Literature DB >> 951390

Drug-induced deafness and its treatment.

J M Ajodhia, M R Dix.   

Abstract

A comprehensive review is presented of the ototoxic effects of drugs which may damage hearing. These have been classified in tabular form together with the recommended dose, method of administration, and ill-effects upon the inner ear. Special emphasis is laid upon the hazard of prescribing such drugs in certain conditions, including in particular the presence of renal or hepatic insufficiency, and the importance of laboratory assessment of new antibiotics for ototoxicity before undertaking clinical trials.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 951390

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


  5 in total

Review 1.  Differences in NSAID tolerability profiles. Fact or fiction?

Authors:  K J Skeith; M Wright; P Davis
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

2.  Ototoxic destruction by co-administration of kanamycin and ethacrynic acid in rats.

Authors:  Hong Liu; Da-lian Ding; Hai-yan Jiang; Xue-wen Wu; Richard Salvi; Hong Sun
Journal:  J Zhejiang Univ Sci B       Date:  2011-10       Impact factor: 3.066

3.  Hearing and cochlear function of patients with ankylosing spondylitis.

Authors:  Orhan Kemal Kahveci; Umit Secil Demirdal; Abidin Duran; Ali Altuntas; Vural Kavuncu; Erdogan Okur
Journal:  Clin Rheumatol       Date:  2012-04-17       Impact factor: 2.980

4.  Middle ear function in rheumatoid arthritis.

Authors:  J N Rosenberg; D A Moffat; R T Ramsden; W P Gibson; J B Booth
Journal:  Ann Rheum Dis       Date:  1978-12       Impact factor: 19.103

5.  Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds.

Authors:  Nazim Bozan; Mahmut Alpaycı; Mehmet Aslan; Hakan Cankaya; Ahmet Faruk Kıroglu; Mahfuz Turan; Abdurrahman Ayral; Emre Senkoy; Server Ilter
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-31       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.